Canada markets open in 5 hours 36 minutes

SHL Telemedicine Ltd. (SZO.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
15.000.00 (0.00%)
As of 02:30PM CEST. Market open.
Full screen
Previous Close15.00
Open15.00
Bid0.00 x 70000
Ask0.00 x 70000
Day's Range15.00 - 15.00
52 Week Range4.28 - 16.50
Volume70
Avg. Volume97
Market Cap220.437M
Beta (5Y Monthly)0.32
PE Ratio (TTM)N/A
EPS (TTM)-0.95
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    SHL Announces Full-Year 2023 Results - Stable Revenue Growth Alongside Groundbreaking Clinical Milestones

    TEL AVIV, Israel & ZURICH & NEW YORK, April 17, 2024--SHL Telemedicine Ltd. (NASDAQ: SHLT; SIX Swiss Exchange: SHLTN) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, announced today its results for the full-year 2023, highlighting fiscally responsible growth across all regions and a strategic focus on expansion and innovation.

  • Business Wire

    Imperial College London Study Shows Groundbreaking Final Results for SHL Telemedicine’s SmartHeart® in Post-ACS Patient Care

    TEL AVIV & ZURICH & NEW YORK, April 11, 2024--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is excited to announce the groundbreaking full results of the Imperial College London TELE-ACS Trial. The randomized clinical trial showcased, among other things, how SHL’s SmartHeart® 12-lead ECG technology can significantly reduce hospital readmissions and ED visits for post-MI (heart attack) pati

  • Business Wire

    SHL Telemedicine’s SmartHeart® Technology Triumphs in US Army Project Convergence – Capstone 4 Experiment

    TEL AVIV, Israel & ZURICH & NEW YORK, April 08, 2024--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions is pleased to share that in a remarkable display of innovation and operational excellence, the Company’s SmartHeart®, portable 12-lead ECG technology showcased its unparalleled capabilities and successfully participated in Project Convergence – Capstone 4 (PC-C4), the largest, two-phase, "in-